NOVATO, Calif., June 01, 2022 (Globe NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: Exceptional), a biopharmaceutical firm targeted on the growth and commercialization of novel therapies for severe unusual and ultra-exceptional genetic illnesses, currently introduced that Emil D. Kakkis, M.D., Ph.D., the firm’s Chief Government Officer and President, will current at the Jefferies World Health care Meeting on Wednesday, June 8, 2022, at 2:30 PM ET in New York.
The reside and archived webcast of the presentation will be accessible from the company’s web-site at http://ir.ultragenyx.com/activities.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical business committed to bringing novel merchandise to clients for the treatment of major uncommon and extremely-rare genetic illnesses. The organization has designed a assorted portfolio of permitted therapies and product or service candidates aimed at addressing diseases with superior unmet health care have to have and obvious biology for procedure, for which there are generally no permitted therapies treating the underlying ailment.
The organization is led by a management crew seasoned in the development and commercialization of scarce disorder therapeutics. Ultragenyx’s method is predicated on time- and cost-productive drug growth, with the target of offering safe and powerful therapies to clients with the utmost urgency.
For much more facts on Ultragenyx, you should go to the firm’s web site at: www.ultragenyx.com.
Ultragenyx Pharmaceutical, Inc.